Hologic's HPV Test Receives FDA Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy HOLX?
Hologic announced that its Aptima HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic's human papillomavirus test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HOLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HOLX
Wall Street analysts forecast HOLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOLX is 77.56 USD with a low forecast of 76.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
0 Buy
12 Hold
0 Sell
Hold
Current: 74.700
Low
76.00
Averages
77.56
High
79.00
Current: 74.700
Low
76.00
Averages
77.56
High
79.00
About HOLX
Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hologic Receives FDA Approval for New HPV Testing
- FDA Approval: Hologic's Aptima® HPV Assay has received FDA approval, becoming the only mRNA-based HPV test, designed to enhance flexibility and choice in cervical cancer screening, which is expected to significantly improve screening efficiency for clinicians.
- Importance of Screening: It is estimated that by 2026, approximately 13,490 new cases of cervical cancer will be diagnosed in the U.S., with about 4,200 women dying from the disease; Hologic's testing can reduce these preventable deaths through early screening and timely follow-up.
- Clinical Research Support: The approval is based on one of the largest real-world HPV screening studies involving over 650,000 women, showing that the sensitivity of the Aptima HPV Assay is clinically comparable to that of an FDA-approved DNA-based HPV test, further enhancing its credibility in clinical applications.
- Diverse Screening Options: Hologic's portfolio now includes Pap + HPV co-testing, Pap testing, and HPV primary testing, providing multiple FDA-approved screening methods that help physicians select the most appropriate testing approach based on patient age and risk factors.
See More
Hologic Q4 Earnings Miss Expectations with Flat Revenue
- Earnings Miss: Hologic reported a Q4 non-GAAP EPS of $1.04, missing expectations by $0.06, indicating pressure on profitability that could undermine investor confidence.
- Flat Revenue: The company’s Q4 revenue stood at $1.05 billion, flat year-over-year but $20 million below market expectations, reflecting weak market demand that may impact future growth strategies.
- Challenging Outlook: Hologic indicated that the outlook for 2026 is more challenging due to halted product shipments, which could lead to a decline in market share, necessitating a reassessment of product lines and market strategies to address these challenges.
- Analyst Rating Watch: Following the earnings miss, analysts' quant ratings on Hologic may be affected, prompting investors to monitor subsequent rating changes to adjust their investment strategies.
See More
Hologic Scheduled to Announce Q4 Earnings on January 29th
- Earnings Announcement Date: Hologic (HOLX) is set to release its Q4 fiscal year 2023 earnings on January 29th after market close, with consensus EPS estimate at $1.10, reflecting a 2.7% year-over-year decline, and revenue estimate at $1.07 billion, indicating a 1.9% year-over-year increase.
- Historical Performance: Over the past two years, Hologic has consistently beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating strong execution in financial forecasting.
- Estimate Revision Trends: In the last three months, EPS estimates have seen five upward revisions and no downward adjustments, while revenue estimates experienced four upward revisions and one downward, indicating growing market confidence in the company's future performance.
- Challenges and Opportunities: Despite facing challenges in product shipments for 2026, Hologic reported a non-GAAP EPS of $1.13, exceeding expectations by $0.03, and revenue of $1.05 billion, surpassing estimates by $20 million, showcasing the company's resilience in maintaining profitability amid adversity.
See More
Analysis and Outlook: The Fed Maintained Its Position, and Markets Followed Suit
- FOMC Meeting Insights: The first FOMC meeting of 2026 provided significant information for Federal Reserve observers.
- Market Reaction: Despite the insights from the meeting, there was little impact on stock market performance.
See More
Key Events to Monitor This Week: Fed Meeting, Apple, Meta, GM, Boeing, Chevron, and Others
Market Performance: Stocks ended the week mostly unchanged after experiencing significant volatility, with the S&P 500 index dropping 2.1% on Tuesday, marking its largest decline since October.
Political Influence: The decline was triggered by President Trump's threats of tariffs on European countries related to his controversial interest in acquiring Greenland from Denmark.
Recovery Efforts: Following the initial drop, the stock market managed to recover most of its losses later in the week.
Trump's Remarks: The recovery was aided by Trump's speech at the World Economic Forum in Davos, where he softened his stance on the tariff threats.
See More
Earnings Reports from Apple and Tech Giants Could Shape Market Direction
- Earnings Season Begins: Apple is set to report earnings next Thursday, with expectations of growth driven by the iPhone 17 replacement cycle, potentially ending its eight-week decline and boosting investor confidence.
- Tech Stocks Under Pressure: Meta and Microsoft are down over 18% from their 52-week highs, Apple is down 13%, and Tesla nearly 10%, setting a low bar for upcoming earnings that may allow these giants to exceed market expectations.
- Small Caps Leading: The Russell 2000 index has rallied over 10% year-to-date, while the S&P 500 is up about 1%, indicating a strong performance from small caps that is further driving overall market gains.
- Federal Reserve Meeting: The upcoming Federal Reserve meeting is expected to keep interest rates steady at 3.50% to 3.75%, with investors keenly awaiting Chair Powell's comments to gauge future monetary policy direction.
See More
Hologic Receives FDA Approval for New HPV Testing
- FDA Approval: Hologic's Aptima® HPV Assay has received FDA approval, becoming the only mRNA-based HPV test, designed to enhance flexibility and choice in cervical cancer screening, which is expected to significantly improve screening efficiency for clinicians.
- Importance of Screening: It is estimated that by 2026, approximately 13,490 new cases of cervical cancer will be diagnosed in the U.S., with about 4,200 women dying from the disease; Hologic's testing can reduce these preventable deaths through early screening and timely follow-up.
- Clinical Research Support: The approval is based on one of the largest real-world HPV screening studies involving over 650,000 women, showing that the sensitivity of the Aptima HPV Assay is clinically comparable to that of an FDA-approved DNA-based HPV test, further enhancing its credibility in clinical applications.
- Diverse Screening Options: Hologic's portfolio now includes Pap + HPV co-testing, Pap testing, and HPV primary testing, providing multiple FDA-approved screening methods that help physicians select the most appropriate testing approach based on patient age and risk factors.
See More
Hologic Q4 Earnings Miss Expectations with Flat Revenue
- Earnings Miss: Hologic reported a Q4 non-GAAP EPS of $1.04, missing expectations by $0.06, indicating pressure on profitability that could undermine investor confidence.
- Flat Revenue: The company’s Q4 revenue stood at $1.05 billion, flat year-over-year but $20 million below market expectations, reflecting weak market demand that may impact future growth strategies.
- Challenging Outlook: Hologic indicated that the outlook for 2026 is more challenging due to halted product shipments, which could lead to a decline in market share, necessitating a reassessment of product lines and market strategies to address these challenges.
- Analyst Rating Watch: Following the earnings miss, analysts' quant ratings on Hologic may be affected, prompting investors to monitor subsequent rating changes to adjust their investment strategies.
See More
Hologic Scheduled to Announce Q4 Earnings on January 29th
- Earnings Announcement Date: Hologic (HOLX) is set to release its Q4 fiscal year 2023 earnings on January 29th after market close, with consensus EPS estimate at $1.10, reflecting a 2.7% year-over-year decline, and revenue estimate at $1.07 billion, indicating a 1.9% year-over-year increase.
- Historical Performance: Over the past two years, Hologic has consistently beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating strong execution in financial forecasting.
- Estimate Revision Trends: In the last three months, EPS estimates have seen five upward revisions and no downward adjustments, while revenue estimates experienced four upward revisions and one downward, indicating growing market confidence in the company's future performance.
- Challenges and Opportunities: Despite facing challenges in product shipments for 2026, Hologic reported a non-GAAP EPS of $1.13, exceeding expectations by $0.03, and revenue of $1.05 billion, surpassing estimates by $20 million, showcasing the company's resilience in maintaining profitability amid adversity.
See More
Analysis and Outlook: The Fed Maintained Its Position, and Markets Followed Suit
- FOMC Meeting Insights: The first FOMC meeting of 2026 provided significant information for Federal Reserve observers.
- Market Reaction: Despite the insights from the meeting, there was little impact on stock market performance.
See More
Key Events to Monitor This Week: Fed Meeting, Apple, Meta, GM, Boeing, Chevron, and Others
Market Performance: Stocks ended the week mostly unchanged after experiencing significant volatility, with the S&P 500 index dropping 2.1% on Tuesday, marking its largest decline since October.
Political Influence: The decline was triggered by President Trump's threats of tariffs on European countries related to his controversial interest in acquiring Greenland from Denmark.
Recovery Efforts: Following the initial drop, the stock market managed to recover most of its losses later in the week.
Trump's Remarks: The recovery was aided by Trump's speech at the World Economic Forum in Davos, where he softened his stance on the tariff threats.
See More
Earnings Reports from Apple and Tech Giants Could Shape Market Direction
- Earnings Season Begins: Apple is set to report earnings next Thursday, with expectations of growth driven by the iPhone 17 replacement cycle, potentially ending its eight-week decline and boosting investor confidence.
- Tech Stocks Under Pressure: Meta and Microsoft are down over 18% from their 52-week highs, Apple is down 13%, and Tesla nearly 10%, setting a low bar for upcoming earnings that may allow these giants to exceed market expectations.
- Small Caps Leading: The Russell 2000 index has rallied over 10% year-to-date, while the S&P 500 is up about 1%, indicating a strong performance from small caps that is further driving overall market gains.
- Federal Reserve Meeting: The upcoming Federal Reserve meeting is expected to keep interest rates steady at 3.50% to 3.75%, with investors keenly awaiting Chair Powell's comments to gauge future monetary policy direction.
See More
